Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERFORM: Pemigatinib in Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
NCT06300528Phase 2Active, not recruiting
- Sponsor
- University of Utah
- Start
- Oct 2025
- Primary completion
- Mar 2026
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of pemigatinib in mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), sponsored by University of Utah. Started Oct 2025; status: active, not recruiting.
02
Drugs
pemigatinib
03
Conditions
mantle cell lymphoma (MCL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT06300528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06300528.